Introducing Renovar™ Advanced Skin and Wound Solution, a proven and versatile solution used for the treatment, debridement, moisturization, and healing promotion of various wound types.
The PennZone/10245630

Trending...
YORK, Pa., Sept. 22, 2023 ~ HR Pharmaceuticals, Inc. has announced the introduction of Renovar™ Advanced Skin and Wound Solution, a non-sensitizing, ready-to-use solution for all wound healing phases. This solution features HOClean™ Technology, a super-oxidized solution that increases the flow of oxygen to the wound bed and speeds up the healing process by 33%. With no known contraindications or side effects, Renovar is safe for cleansing the wound, relieving irritation, and reducing the risk of infection.

Chris Wiesman, Chief Revenue Officer at HRP said: "We are excited to introduce the Renovar product portfolio to the market. It complements our existing portfolio of medical consumables and presents a solid opportunity for us to expand into wound care. We look forward to working with our customers across the continuum of care to drive value and positively impact people's lives."

Renovar Skin and Wound Solution is clinically proven to provide at least a 99.9% reduction of most microorganisms. It demonstrates in-vitro activity against a broad spectrum of gram-negative and gram-positive bacteria while breaking down biofilm in just 30 seconds, allowing healthy tissue to form and reducing the risk of infection. Colby Wiesman, Chief Executive Officer at HRP said: "With an expected 7-10% annual growth over the next five years, we see the wound care market as attractive. We recognize the clinical and technical aspects of Wound Care and have strategically selected a niche segment for entry where we can make an immediate impact and move market share."

More on The PennZone
HR Pharmaceuticals Inc., has introduced Renovar™ Advanced Skin and Wound Solution as an effective solution for all wound healing phases with no known contraindications or side effects. This solution features HOClean™ Technology which increases oxygen flow to speed up healing by 33%. It is clinically proven to provide at least 99.9% reduction of most microorganisms while breaking down biofilm in just 30 seconds allowing healthy tissue formation with reduced risk of infection. Chris Wiesman, Chief Revenue Officer said they are excited about this product portfolio which presents an opportunity for them to expand into wound care while Colby Wiesman, Chief Executive Officer sees potential growth in this market segment over next five years with their strategic entry into this niche segment. To learn more about this product offering visit http://renovarwoundcare.com/.
Show All News | Disclaimer | Report Violation

0 Comments

Latest on The PennZone